Every material Form 8-K Dogwood Therapeutics, Inc. has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Dogwood Therapeutics reported a third-quarter 2026 net loss of $4.9 million, or $0.14 per share, compared with $15.7 million, or $8.20 per share, a year earlier, as research and development expenses fell from $14.5 million to $3.3 million. The company completed enrollment of 239 patients in its Halneuron Phase 2b CINP study, with top-line results expected in November 2026, and closed a $5 million private placement with its largest shareholder, which it said provides runway through the first quarter of 2027.
Q3 2026 licensing revenue of $0.1 million, compared with no revenue in Q3 2025.
R&D expenses of $3.3 million versus $14.5 million; the prior-year period included a $12.0 million acquired IPR&D charge tied to the Serpin Licensing Agreement.
$5 million private placement with Sealbond Limited, a subsidiary of CK Life Sciences Int'l., (Holdings) Inc.; cash on hand of $4.9 million.
Top-line results from the Halneuron Phase 2b CINP study expected in November 2026.
Dogwood Therapeutics agreed on October 19, 2026 to sell 4,098,360 shares of common stock at $1.22 per share to Sealbond Limited, a subsidiary of its largest shareholder, in a private placement with expected gross proceeds of about $5 million before offering expenses. The company says the proceeds will extend its operational runway through March 2027 and fund Phase 3 preparatory work, and the issuance adds new shares that dilute existing holders.
4,098,360 shares of common stock at $1.22 per share, with expected gross proceeds of about $5 million before offering expenses
Sealbond beneficially owned about 63.9% of outstanding common stock before the placement and is considered an affiliate
Closing is expected on or before October 29, 2026; the company must file a resale registration statement by the 15th day after the October 19, 2026 agreement
The press release says proceeds will fund Phase 3 preparatory activities and extend runway through March 2027, ahead of HAL-CINP Phase 2b topline data expected in November 2026
Dogwood Therapeutics reported a second-quarter 2026 net loss attributable to common stockholders of $11.5 million, or $0.34 per share, compared with $3.8 million, or $1.99 per share, a year earlier. The loss increase reflects a $9.2 million non-cash IPR&D impairment, and the company reported no revenue in either period. The company said the impairment does not affect its cash runway, which it stated extends through the Phase 2b Halneuron readout in the fourth quarter of 2026.
Q2 2026 net loss of $11.5 million versus $3.8 million in Q2 2025; no revenue in either period
IPR&D impairment of $9.2 million in Q2 2026, partly offset by a $2.5 million deferred tax benefit, for a net impairment of $6.7 million
R&D expenses rose to $3.2 million from $2.6 million; G&A rose to $1.6 million from $1.3 million
Cash of $9.6 million at June 30, 2026, which the company says funds operations through the Phase 2b readout in Q4 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Dogwood Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →